{
  "docId": "019dd923-622c-750b-8b9a-40e2965928db",
  "docSlug": "e5bffbaac707",
  "documentTitle": "TransMedics (TMDX)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2025-01-10 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 316,
  "pageCount": 342,
  "prevPage": 315,
  "nextPage": 317,
  "slideType": "quote_slide",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "Includes verbatim transcripts from a transplant surgeon regarding competitive dynamics in the liver transplant market.",
  "elementsJson": [
    "paragraph",
    "quote_block",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-40e2965928db/316",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-40e2965928db",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-40e2965928db.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-40e2965928db#slide-316",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Top liver centers who were involved with TransMedics have defected to LifePort",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-5374-767b-b3bd-2d109e4b94b7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.86,
        "x": 0.07,
        "y": 0.22
      },
      "kind": "paragraph",
      "text": "In addition, he pointed to VitaSmart’s hypothermic system which uses a temperature of 4 to 12 degrees Celsius to reduce an organ’s metabolic rate to 10% of normal and prevents re-perfusion injury common with TransMedics pump.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "016d7e9d-b411-4fd9-b57e-398bd6df2081",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.86,
        "x": 0.07,
        "y": 0.72
      },
      "kind": "quote",
      "text": "The study that was the basis of the FDA submission for TransMedics for their liver approval was JAMA surgery in 2022... The decreases in EAD were fairly equivalent, which surprised a lot of people...",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "38356584-f728-4d0d-a85a-4e53bef30a39",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.86,
        "x": 0.07,
        "y": 0.5
      },
      "kind": "quote",
      "text": "The LifePort study is a really good example. These are centers; some were in the TransMedics trial, but they clearly jumped ship to be involved with LifePort...",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "77980717-cad5-4f45-88da-dcca64ed6cdc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "“The LifePort study is a really good example. These are centers; some were in the TransMedics trial, but they clearly jumped ship to be involved with LifePort...that’s the device that a lot of really big names in the field in liver really think is going to be very, very competitive with TransMedics” — Transplant surgeon, Director of a leading academic transplant center",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-5374-767b-b3bd-33338d3e8649",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.07,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Scorpion Capital consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2434d346-f9d1-42d9-ac98-b371527aeddd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.86,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "title",
      "text": "The KOL stated that top liver centers – “really big names in the field” – from the TransMedics trial have already defected to LifePort",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5912d1fa-9172-49a6-b69b-d5c6dd732d15",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "authority-citation",
      "slug": null,
      "matchId": "d09578ae-b2aa-4c73-9cb2-bac66c2a206d",
      "evidence": "Use of KOL (Key Opinion Leader) quotes to validate competitive claims.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}